Advancing Public Health Through Vaccination: A Narrative Review of Respiratory Syncytial Virus (RSV) Immunization Strategies

Year : 2024 | Volume :14 | Issue : 01 | Page : 1-6
By

    Vaishnavi Velmani

  1. Sriram Radhakrishnan

  1. Student, C.L. Baid Metha College of Pharmacy (Affiliated to The Tamil Nadu Dr. MGR Medical University), Chennai, India
  2. Student, C.L. Baid Metha College of Pharmacy (Affiliated to The Tamil Nadu Dr. MGR Medical University), Chennai, India

Abstract

RSV is a significant factor in causing lower respiratory tract infections in children, especially among infants and toddlers. Different age groups are affected by RSV in distinct ways, specifically affecting young children and elderly. People who are immunocompromised are more susceptible to RSV. Centres for Disease Control and Prevention has recommended vaccination doses with the age group to prevent mortality associated with RSV. Signs and symptoms often resemble common cold in coughing, decreased appetite, runny nose, etc. Additionally, RSV not only provides protection to the pregnant mother, but also to the growing fetus. If the mother had taken immunization within the past 14 days of childbirth, the child until his/her 8 months is not necessary to take additional RSV vaccine, as the vaccine taken by mother provides protection for the child. Hospitalizations are mostly required in severe elderly RSV- associated pneumonia. Coordination of immunization strategies, awareness and suitable protocol of administration may help reach out to people at risk of getting RSV infection. Monoclonal antibodies plays an important role in preventing RSV infections. Several ongoing and future studies may help reveal clues towards more advanced immunization practices. Continued research and investment in RSV immunization efforts are crucial for achieving long-term public health goals and reducing the global impact of this infectious disease. Beyond several challenges that hurdle the vaccine development and administration, vaccines are administered and they help in reducing the global burden by preventing RSV-associated hospitalization and mortality in all age groups.

Keywords: Respiratory syncytial virus (RSV), immunization, monoclonal antibody, vaccines, signs and symptoms, public health, fetal protection.

[This article belongs to Research & Reviews : A Journal of Immunology(rrjoi)]

How to cite this article: Vaishnavi Velmani, Sriram Radhakrishnan.Advancing Public Health Through Vaccination: A Narrative Review of Respiratory Syncytial Virus (RSV) Immunization Strategies.Research & Reviews : A Journal of Immunology.2024; 14(01):1-6.
How to cite this URL: Vaishnavi Velmani, Sriram Radhakrishnan , Advancing Public Health Through Vaccination: A Narrative Review of Respiratory Syncytial Virus (RSV) Immunization Strategies rrjoi 2024 {cited 2024 Apr 24};14:1-6. Available from: https://journals.stmjournals.com/rrjoi/article=2024/view=144252


References

  1. Hall CB. Respiratory syncytial virus and parainfluenza virus. New England journal of medicine. 2001 Jun 21;344(25):1917-28.
  2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375[9725]:1545-1555. DOI: 10.1016/S0140-6736[10]60206-160206-1]
  3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352[17]:1749-1759. DOI: 10.1056/NEJMoa043951
  4. American Academy of Pediatrics Committee on Infectious Diseases. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134[2]:415-420. DOI: 10.1542/peds.2014-1665
  5. Piralla A, Chen Z, Zaraket H. An update on respiratory syncytial virus. BMC Infectious Diseases. 2023 Oct 27;23(1):734.
  6. Centers for Disease Control and Prevention [CDC]. Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children. Emerg Infect Dis. 2020;26[7]:1537-1543. DOI: 10.3201/eid2607.190539
  7. World Health Organization. The Burden of Respiratory Viruses and Their Prevalence in the World. Front Microbiol. 2021;12:723850. DOI: 10.3389/fmicb.2021.723850
  8. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children. Lancet. 2022;399[10300]:682-694. DOI: 10.1016/S0140-6736[22]00478-000478-0]
  9. Piralla A, Chen Z, Zaraket H. An update on respiratory syncytial virus. BMC Infect Dis. 2023; 23:734. DOI: 10.1186/s12879-023-08730-x
  10. Preventing RSV (Respiratory Syncytial Virus). Centers for Disease Control and Prevention. 2024. Available from: https://www.cdc.gov/rsv/about/prevention.html#:~:text=CDC%20recommends%20immunizations%20to%20protect,the%20likelihood%20of%20spreading%20RSV.
  11. RSV [Respiratory Syncytial Virus] Vaccination | CDC. www.cdc.gov. 2023. Available from: https://www.cdc.gov/vaccines/vpd/rsv/index.html
  12. US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus [RSV] vaccine for older adults | GSK. www.gsk.com. 2023. Available from: https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/
  13. Shimabukuro T. Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases Post-licensure safety monitoring of respiratory syncytial virus [RSV] vaccines in adults aged ≥60 years Advisory Committee on Immunization Practices [ACIP]. 2024. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-02-28-29/05-RSV-Adults-Shimabukuro-508.pdf
  14. ACIP Evidence to Recommendations for Use of Nirsevimab in Children 8–19 months of age with increased risk of severe disease entering their second RSV season | CDC. www.cdc.gov. 2023. Available from: https://www.cdc.gov/vaccines/acip/recs/grade/nirsevimab-season2-rsv-infants-children-etr.html
  15. Respiratory Syncytial Virus vaccines [RSV] Options for Infant RSV Prevention At-a-Glance. Available from: https://www.cdc.gov/vaccines/vpd/rsv/downloads/Infant-RSV-Prevention-At-A-Glance.pdf
  16. American Academy of Pediatrics Committee on Infectious Diseases. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134[2]:415-420. DOI: 10.1542/peds.2014-1665
  17. Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18[10]:e295-e311. DOI: 10.1016/S1473-3099[18]30139-030139-0]
  18. gov. A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants [MELODY]. https://classic.clinicaltrials.gov/ct2/show/NCT03979313
  19. Respiratory Syncytial Virus Vaccines: A Landscape Analysis, https://www.path.org/our-impact/resources/rsv-vaccine-and-mab-snapshot/
  20. Health and Human Services. Respiratory Syncytial Virus [RSV] Vaccines. https://www.hhs.gov/immunization/diseases/rsv/index.html
Regular Issue Subscription Review Article
Volume 14
Issue 01
Received March 21, 2024
Accepted March 21, 2024
Published April 24, 2024
Views: 33